Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

Reporting results of cancer treatment

1981 • 7,916 citations

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

1985 • 2,298 citations

DNA TOPOISOMERASES

1985 • 1,524 citations

Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

1989 • 1,030 citations

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

1991 • 855 citations

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

1988 • 843 citations

The Current Status of Camptothecin Analogues as Antitumor Agents

1993 • 614 citations

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

1989 • 533 citations

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

1994 • 503 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

1987 • 412 citations

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1972 • 315 citations

Phase I and pharmacokinetic trial of weekly CPT-11.

1993 • 300 citations

Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.

1990 • 292 citations

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1991 • 275 citations

Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

1970 • 246 citations

Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I.

1989 • 243 citations

Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea

1994 • 242 citations

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1990 • 234 citations

Studies on the Antitumor Activity, Mechanism of Action, and Cell Cycle Effects of Camptothecin

1971 • 213 citations

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1988 • 213 citations

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1994 • 195 citations

Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells.

1991 • 159 citations

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.

1994 • 151 citations

Nonlinear pharmacokinetics of CPT-11 in rats.

1990 • 109 citations

Toxicity of camptothecin (NSC-100880).

1974 • 81 citations

Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients

1992 • 76 citations

Lethal activity of camptothecin sodium on human lymphoma cells.

1974 • 54 citations

[Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].

1990 • 25 citations